NTRA Stock: Price, Earnings History and SEC Filings
Natera, Inc. (NTRA) last traded at $414.30, down 4.98% on the latest session and up 0.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.47 against an analyst estimate of $-0.47, a beat of 0.0%.
$414.30 -4.98%
1 month+0.24%
52-week high$437.41
52-week low$181.00
Volume2.43M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NTRA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.47 | $-0.47 | +0.00% |
| Mar 2026 | May 7, 2026 | $-0.56 | $-0.53 | -5.66% |
| Dec 2025 | Feb 26, 2026 | $0.35 | $-0.46 | +176.09% |
| Sep 2025 | Nov 6, 2025 | $-0.64 | $-0.39 | -64.10% |
NTRA beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for NTRA
SEC filing data is not available right now. You can search for NTRA on SEC EDGAR.
NTRA news
- Natera stock heads into November 5 results after oncology dataNov 1, 2026 · ad-hoc-news.de
- CareDx Soars 20% on Big Q3 Beat and Guidance RaiseOct 30, 2026 · tikr.com
- When The Stock Market Is Choppy, It Pays To Watch This Technical SetupOct 30, 2026 · finance.yahoo.com
- Global Genetic Counseling Services Market Report 2026 | Capitalize on AI and Telehealth as Market Hits $4.67 Billion by 2030: Labcorp, Quest Diagnostics, Natera, GeneDxOct 30, 2026 · finance.yahoo.com
- Illumina Sinks 13% on Light Q3 Revenue Despite EPS Beat and Raised GuidanceOct 30, 2026 · tikr.com
- CareDx (CDNA) Surpasses Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Global Pan-Ethnic Carrier Screening Programs Market Report 2026 | Capitalize on 14.1% CAGR as Illumina, Natera, Fulgent Genetics and LabCorp Scale AI and Multi-Gene PanelsOct 29, 2026 · finance.yahoo.com
- Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
About Natera, Inc.
Natera, Inc. (NTRA) is a US-listed public company on Nasdaq.